APG 2575

Lisaftoclax (APG-2575) is Ascentage Pharma's oral BCL-2 inhibitor. It was approved by China's National Medical Products Administration (NMPA) in July 2025 for adults with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL) who have received at least one prior systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors [11]. It is now in a global Phase 3 trial in the same population (NCT06104566) [1], making it one of two selective BCL-2 inhibitors currently in Phase 3, alongside BeiGene's sonrotoclax (BGB-11417) [10]. Both chase AbbVie's venetoclax (Venclexta), the class-defining approved drug generating roughly $2.6 billion in 2024 sales [8]. Ascentage's separate June 2024 option agreement with Takeda covers olverembatinib (a BCR-ABL inhibitor for CML), not lisaftoclax [2]; lisaftoclax remains wholly-owned by Ascentage outside the deal.

Lisaftoclax is a novel small molecule, approved to date only in China (NMPA, July 2025) for R/R CLL/SLL post-BTK-inhibitor [11]. There is no US or EU (European Medicines Agency, EMA) approval. The lead ex-China program is NCT06104566, a global randomized Phase 3 study in R/R CLL/SLL with an enrollment target of 400 [1]. Recruitment is active across North American, European, and Chinese sites. The AML/MDS program is a Phase 1 combination study with azacitidine, a hypomethylating agent that reactivates silenced tumor-suppressor genes and is standard-of-care in older/unfit AML (NCT04501120, n=682 planned), with recent Chinese data showing tolerable safety and preliminary activity in R/R AML/MDS [3]. A Phase 1b/2 CLL monotherapy and combination study reported in 2025 (Davids et al., Med) documented acceptable safety and activity signals across dose escalation, including responders on background BTK inhibitor therapy [4]. A separate Phase 1 study in Chinese R/R CLL/SLL patients reported dose-escalation safety and pharmacokinetics consistent with the Western dataset [5]. A Phase 1 trial in mild-to-moderate systemic lupus erythematosus (SLE) (NCT06182969, n=40) is enrolling, testing an autoimmune expansion for the same apoptotic-brake mechanism [6]. No FDA Breakthrough Therapy designation has been publicly disclosed for lisaftoclax. Based on current recruitment status for the global Phase 3, a primary progression-free survival (PFS) readout is unlikely before 2028, and a US New Drug Application (NDA, the FDA approval package) timing depends on interim analyses and Ascentage's ex-China commercial strategy.

BCL-2 is the cell's brake on suicide. Every cell carries an internal self-destruct program called apoptosis, wired for when things go wrong: DNA damage, viral infection, developmental cleanup. BCL-2 sits on the mitochondrial membrane and prevents that program from firing [7]. Cancer cells, especially B-cell malignancies like CLL, ramp up BCL-2 expression so that even damaged, mutated cells refuse to die. Blocking BCL-2 releases the brake and the cancer cells kill themselves. Lisaftoclax is a BH3-mimetic. Normal cells use small proteins called BH3-only proteins to unlatch BCL-2's grip on pro-death factors like BAX and BAK. Lisaftoclax mimics that BH3 helix, wedging into BCL-2's binding groove and letting BAX/BAK punch holes in the mitochondrial membrane. Cytochrome c leaks out, caspases activate, cell dies. The mechanism is thoroughly validated. AbbVie's venetoclax, the first approved BCL-2 selective inhibitor, is standard-of-care in CLL and first-line AML and generated roughly $2.6 billion in 2024 sales [8]. That commercial track record is a green light: the target works, the biology is clean, and hematologists know how to use these drugs. Lisaftoclax's own China NMPA approval in July 2025 [11] further reduces mechanism risk for this specific molecule. Selectivity matters. BCL-XL, a close relative of BCL-2, keeps platelets alive. Drugs that hit both cause severe thrombocytopenia (a dangerous drop in platelet count), which killed navitoclax's development. Lisaftoclax is designed to spare BCL-XL, following venetoclax's playbook. That is a solved problem at the chemistry level. The open question is whether lisaftoclax works differently enough to matter commercially against venetoclax and sonrotoclax.

The lead ex-China study is NCT06104566, a global Phase 3 randomized trial in adults with R/R CLL/SLL, enrolling 400 patients across North America, Europe, and Asia [1]. Primary endpoint is progression-free survival by independent review. The comparator is investigator's choice standard therapy, which given the population likely includes BTK inhibitor combinations (BTK inhibitors, oral drugs like ibrutinib, acalabrutinib, and zanubrutinib, are the dominant first-line CLL therapy) or chemoimmunotherapy depending on prior lines. Recruitment status is active as of mid-2026. Design strengths: multi-regional to satisfy FDA and EMA (European Medicines Agency) data expectations, PFS is the accepted regulatory endpoint in CLL, and the R/R population has a clear unmet need after patients have failed BTK inhibitors or cannot tolerate or have progressed on venetoclax. Weaknesses worth flagging: there is no direct head-to-head against venetoclax, so any approval will leave the differentiation question unresolved by the key data itself. Investigator's-choice comparators are also easier to beat than a defined active control, and both regulators and payers know it. The AML Phase 1 (NCT04501120) is unusually large at 682 planned patients, functioning as a seamless Phase 1/2 across multiple combinations with hypomethylating agents like azacitidine and decitabine [3]. The SLE Phase 1 (NCT06182969) is small (n=40) and pharmacokinetics-focused, an early bet on depleting autoreactive B cells through apoptosis rather than the CD19/CD20 antibody route that dominates autoimmune B-cell therapy today [6].

Our model estimates a 12% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by the sponsor's thin or weak approval record, smaller-than-typical enrollment for this phase, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy: the biggest risk is not that lisaftoclax fails to work, but that it fails to differentiate from venetoclax and sonrotoclax. Without a head-to-head trial, approval will depend on cross-trial comparison, which is regulatory-acceptable in CLL but commercially thin. If ORR and PFS land at parity with historical venetoclax data, payers will push back hard and prescribers may default to the incumbent. Safety: tumor lysis syndrome is the class-defining hazard. Rapid B-cell killing dumps intracellular contents into the bloodstream and can crash kidney function or trigger fatal arrhythmias. Venetoclax requires a five-week weekly ramp-up with hospitalization for high-risk patients. Ascentage has publicly stressd a faster daily ramp for lisaftoclax with a lower reported TLS incidence, and the Chinese registrational trial reported zero on-study TLS events [11]. If the global Phase 3 confirms that claim in a Western, higher-baseline-tumor-burden population, that is genuine differentiation: shorter ramp means faster time to therapeutic dose and lower monitoring burden, which matters in community oncology settings. If TLS incidence matches or exceeds venetoclax in the global trial, the marketing story collapses. Execution: this is Ascentage's first global Phase 3. Chinese biotechs have had mixed results translating domestic clinical operations into multi-regional trials that satisfy FDA data-integrity standards. Commercial: even with clean data, lisaftoclax enters a market where venetoclax has a decade of prescriber familiarity. Venetoclax patent protection in the US extends into the early 2030s (drugpatentwatch estimates generic launch around September 2033, though the FDA tentatively approved a Dr Reddy's generic in May 2026 with launch gated by patent litigation) [12], so lisaftoclax should face a branded-only US market at launch. BeiGene's sonrotoclax is also in Phase 3 with potentially deeper responses in early data [10]. Third-mover economics in CLL are not obvious unless a specific niche, such as post-venetoclax salvage or faster ramp for outpatient settings, is carved out and validated.

Worth watching. The mechanism is real, the molecule has a China approval anchoring commercial viability at home, and R/R CLL patients past venetoclax and BTK inhibitors need something new. R/R CLL/SLL represents roughly 15,000 to 20,000 US patients annually with limited post-BTK/venetoclax options, a population with documented willingness-to-pay given the unmet need. Specific signals to track: First, updated Phase 1b/2 and global Phase 3 safety data at ASH 2026 or EHA 2027, especially TLS incidence and rapid-ramp feasibility in Western patients with high tumor burden. If Ascentage can reproduce the Chinese zero-TLS result on a US cohort with the sub-24-hour ramp, that is genuine differentiation. Second, whether Ascentage secures a Western partner for lisaftoclax. The June 2024 Takeda option was for olverembatinib, not lisaftoclax, so lisaftoclax remains unpartnered ex-China [2]. A large-pharma partnership specifically covering lisaftoclax would meaningfully de-risk global launch. Third, Phase 3 interim analyses. The 400-patient NCT06104566 is unlikely to report primary PFS before 2028, but interim safety and enrollment updates through 2027 will telegraph execution quality and site activation pace. Fourth, Ascentage cash runway. Management guided funding through 2027 as of March 2025, combining $172.8M in cash at end-2024, the $100M Takeda option payment and $75M Takeda equity for olverembatinib, and $132.5M in IPO net proceeds from January 2025 [13]. Investors should track quarterly burn: without a lisaftoclax-specific ex-China deal, a dilutive raise before Phase 3 primary readout is plausible. Skip the SLE Phase 1 as a near-term value driver. It is too early and B-cell depletion through BCL-2 inhibition in autoimmunity is unproven, competing with a wall of anti-CD19/CD20 approaches. Check back after the next major hematology conference cycle for the first meaningful update on the global Phase 3.